ASCO has issued new clinical guidance for best treating patients with gastrointestinal (GI) cancer amidst a nationwide shortage of carboplatin and cisplatin.
June 5, 2023
June 5, 2023
Ciltacabtagene autoleucel (Carvykti®), a BCMA-targeting CAR T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among those for whom lenalidomide no longer works. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2023
Trastuzumab deruxtecan (Enhertu®) is an effective treatment option for people with difficult-to-treat HER2-expressing solid tumors, according to the findings of an international study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
An immune checkpoint inhibitor, nivolumab (Opdivo®), plus chemotherapy significantly reduced the risk of disease progression and disease-related death compared with standard treatment with the CD30-targeted drug brentuximab (Adcetris®) plus chemotherapy in pediatric and adult patients with previously untreated stage III or IV Hodgkin lymphoma. The results of the federally funded clinical trial will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
MIRASOL, an international phase III randomized clinical trial, found that mirvetuximab soravtansine (Elahere™), an antibody and microtubule inhibitor conjugate, significantly improved progression-free and overall survival for women with platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Treatment with osimertinib (Tagrisso®) after surgery significantly lowered the risk of death in adults with completely resected EGFR-mutated (EGFRm) stage IB, II, or IIIA non-small cell lung cancer (NSCLC), according to the findings of an international study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 gliomas, a type of malignant brain tumor with poor long-term prognosis. This treatment delayed disease progression and was well-tolerated. These findings represent a significant step forward in the treatment of grade 2 glioma with IDH mutations. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of federally funded research that will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the New England Journal of Medicine (efficacy) and the Journal of Clinical Oncology (patient reported outcomes) on June 4, 2023. Omitting radiation therapy can reduce short- and long-term side effects that impact quality of life while providing similar outcomes in disease-free survival and overall survival.
June 3, 2023
People with newly diagnosed advanced ovarian cancer without BRCA mutations, who received durvalumab (Imfinzi®) and olaparib (Lynparza®) in addition to the standard of care had improved progression-free survival compared with those who received the standard of care only, according to the interim analysis of DUO-O, an international phase III randomized clinical trial. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 2, 2023
Adding the targeted therapy drug ribociclib (Kisqali®) to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 2, 2023
Simple hysterectomy with pelvic node dissection is a safe treatment option for people with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from a large, international phase III clinical trial. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 31, 2023
Today the U.S. House is poised to vote on legislation to raise the nation’s debt ceiling. The proposal includes flat funding for non-defense discretionary spending in FY 2024 and a 1% funding increase in FY 2025. This would considerably restrict potential resources for the National Institutes of Health (NIH) and National Cancer Institute (NCI) at a time when scientists are on the cusp of so many promising cancer discoveries.
May 25, 2023
Adding the immunotherapy drug pembrolizumab (Keytruda®) to chemotherapy, with or without bevacizumab (Avastin®), improved overall survival (OS) and progression-free survival (PFS) in people with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
People with lower-risk myelodysplastic syndromes (MDS) who received luspatercept (Reblozyl®) to treat anemia instead of erythropoiesis-stimulating agents (ESAs), the current standard of care, needed fewer blood transfusions and clinic visits. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 25, 2023
Patients with breast cancer in the overweight or obese body mass index (BMI) ranges can achieve meaningful weight loss through a telephone-based intervention. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pages |